True Freedom Investing LLC Makes New $3.33 Million Investment in DexCom, Inc. $DXCM

True Freedom Investing LLC bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 53,078 shares of the medical device company’s stock, valued at approximately $3,333,000.

A number of other institutional investors have also recently modified their holdings of the business. Brighton Jones LLC raised its holdings in DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after purchasing an additional 11,946 shares during the period. Integrated Wealth Concepts LLC boosted its position in DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after purchasing an additional 196 shares in the last quarter. Empowered Funds LLC grew its holdings in DexCom by 5.4% in the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after purchasing an additional 436 shares during the period. Focus Partners Wealth grew its holdings in DexCom by 13.2% in the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after purchasing an additional 841 shares during the period. Finally, NewEdge Advisors LLC increased its position in shares of DexCom by 1.4% in the second quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock valued at $1,681,000 after buying an additional 258 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on DXCM shares. Weiss Ratings raised DexCom from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 11th. Argus lifted their price target on shares of DexCom from $86.00 to $96.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Stifel Nicolaus set a $95.00 price target on shares of DexCom and gave the stock a “buy” rating in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft started coverage on shares of DexCom in a research report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 price objective for the company. Finally, Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $88.71.

Insider Transactions at DexCom

In related news, insider Kevin R. Sayer sold 26,756 shares of the stock in a transaction on Monday, July 20th. The stock was sold at an average price of $76.32, for a total value of $2,042,017.92. Following the completion of the transaction, the insider directly owned 328,970 shares of the company’s stock, valued at approximately $25,106,990.40. This represents a 7.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 2,000 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $85.32, for a total value of $170,640.00. Following the completion of the transaction, the director owned 48,852 shares in the company, valued at $4,168,052.64. The trade was a 3.93% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 73,035 shares of company stock valued at $5,446,673 over the last ninety days. Company insiders own 0.28% of the company’s stock.

DexCom Price Performance

NASDAQ:DXCM opened at $92.34 on Friday. The stock has a 50 day moving average of $77.49 and a two-hundred day moving average of $70.94. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $92.56. The firm has a market cap of $34.85 billion, a P/E ratio of 36.50, a price-to-earnings-growth ratio of 1.56 and a beta of 1.41. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.09. The business had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.48 earnings per share. On average, analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.